Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Votre recherche
Pays: Israel,Lithuania,France,Netherlands,Greece,Germany,Portugal,Poland,Hungary,Austria
nct
MAJ Il y a 5 ans
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
The purpose of this study is to collect information on how effective and how well tolerated an oral investigational drug is compared to a standard intravenous drug in patients with pretreated, advanced non-small lung cancer (NSCLC).
Pays
Australia
,
Austria
,
Belgium
,
Canada
,
China
,
Czech Republic
,
Denmark
,
Finland
,
France
,
Germany
,
Greece
,
Hungary
,
Israel
,
Italy
,
Latvia
,
Lithuania
,
Netherlands
,
New Zealand
,
Philippines
,
Poland
,
Portugal
,
Russian Federation
,
Singapore
,
South Africa
,
Spain
,
Switzerland
,
Taiwan, Province of China
,
Thailand
,
Turkey
,
Ukraine
,
United Kingdom
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
This purpose of this study is to assess the safety of ustekinumab in psoriasis patients who receive ustekinumab following an inadequate response to methotrexate therapy. The study will provide information for doctors on how to manage the transfer from methotrexate to the biologic agent ustekinumab. The study is designed to compare two methods of transferring patients from methotrexate to ustekinumab. The two methods being compared are discontinuation of methotrexate with immediate initiation of ustekinumab versus initiation of ustekinumab with overlap and gradual dose reduction of methotrexate over 4 weeks.
Pays
Austria
,
Belgium
,
Bulgaria
,
Denmark
,
Finland
,
France
,
Germany
,
Greece
,
Hungary
,
Israel
,
Lithuania
,
Netherlands
,
Norway
,
Poland
,
Portugal
,
Slovakia
,
Spain
,
Sweden
,
United Kingdom
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
1